~~<i id='326913F404'><strike id='326913F404'><tt id='326913F404'><pre id='326913F404'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：fashion 2025-08-12 11:33:42 - browse：25

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Dems pitch expanding Medicare power to negotiate drug prices

explore

knowledge

focus

hotspot

AnewlawsuitaccusesthehealthinsurerCignaofdenyingclaimsinbulk.JuliaRendleman/GettyImagesforEventiveMa

WSS

The battle over 'scope creep' and who gets to be called 'doctor'

Will an HIV vaccine ever be a reality?

Search called off for baby washed away in Pennsylvania flash flood

Democrats decry new health bill for going easy on private equity

Flu, Covid vaccination rates decline, new survey data show

New oral drug delivery patch is modeled after octopus tentacles

entertainment

explore

explore

Cancer drug shortages should be causing more outrage

'Investigate these claims': UFO transparency at center of House hearing

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Wildfire smoke exposes gaps in outdoor worker protections

Former reverend arrested for allegedly killing 8

New air purifier tech could be key to improving indoor air quality

Former reverend arrested for allegedly killing 8

United colonoscopy coverage change 'may cost lives,' doctors say

2023 Nobel Prize in Medicine goes to Karikó and Weissman

knowledge

Democrats decry new health bill for going easy on private equity

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Will the FTC rein in IQVIA's health data empire?

What we owe ALS patients — and why one company fell short

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Biogen says it will cut costs by $700 million, slash 1,000 jobs

focus

focus

hotspot

hotspot